HK1197025A1 - 即釋 -甲基- -吡啶基 -嘧啶基 氨基 -甲基- -咪唑- -基 三氟甲基 苯基 苯甲酰胺劑型 - Google Patents
即釋 -甲基- -吡啶基 -嘧啶基 氨基 -甲基- -咪唑- -基 三氟甲基 苯基 苯甲酰胺劑型Info
- Publication number
- HK1197025A1 HK1197025A1 HK14110470A HK14110470A HK1197025A1 HK 1197025 A1 HK1197025 A1 HK 1197025A1 HK 14110470 A HK14110470 A HK 14110470A HK 14110470 A HK14110470 A HK 14110470A HK 1197025 A1 HK1197025 A1 HK 1197025A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methyl
- imidazol
- pyridinyl
- pyrimidinyl
- trifluoromethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161559281P | 2011-11-14 | 2011-11-14 | |
PCT/US2012/064610 WO2013074432A1 (en) | 2011-11-14 | 2012-11-12 | Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1197025A1 true HK1197025A1 (zh) | 2015-01-02 |
Family
ID=47324402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14110470A HK1197025A1 (zh) | 2011-11-14 | 2014-10-21 | 即釋 -甲基- -吡啶基 -嘧啶基 氨基 -甲基- -咪唑- -基 三氟甲基 苯基 苯甲酰胺劑型 |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP2779995A1 (zh) |
JP (1) | JP6275645B2 (zh) |
KR (1) | KR20140093230A (zh) |
CN (1) | CN103930094A (zh) |
AR (1) | AR088844A1 (zh) |
BR (1) | BR112014011518A2 (zh) |
CA (1) | CA2855503A1 (zh) |
CL (1) | CL2014001247A1 (zh) |
CO (1) | CO6960546A2 (zh) |
EA (1) | EA201490960A1 (zh) |
GT (1) | GT201400094A (zh) |
HK (1) | HK1197025A1 (zh) |
IL (1) | IL232480A0 (zh) |
IN (1) | IN2014DN03416A (zh) |
MA (1) | MA35636B1 (zh) |
MX (1) | MX2014005874A (zh) |
PE (1) | PE20141337A1 (zh) |
SG (2) | SG11201401476TA (zh) |
TN (1) | TN2014000177A1 (zh) |
TW (1) | TWI574690B (zh) |
WO (1) | WO2013074432A1 (zh) |
ZA (1) | ZA201402756B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
CZ2017821A3 (cs) | 2017-12-20 | 2019-07-03 | Zentiva, K.S. | Léková forma obsahující krystalický nilotinib |
JP7378279B2 (ja) | 2019-11-18 | 2023-11-13 | 日本化薬株式会社 | ニロチニブを有効成分とする医薬錠剤及びその製造方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
EP1923053A1 (en) * | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
US20100136097A1 (en) * | 2008-12-02 | 2010-06-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Systems for modulating inflammation |
IN2011CH01887A (zh) * | 2011-06-02 | 2012-12-14 |
-
2012
- 2012-11-12 WO PCT/US2012/064610 patent/WO2013074432A1/en active Application Filing
- 2012-11-12 AR ARP120104259A patent/AR088844A1/es unknown
- 2012-11-12 KR KR1020147012521A patent/KR20140093230A/ko not_active Application Discontinuation
- 2012-11-12 CA CA2855503A patent/CA2855503A1/en not_active Abandoned
- 2012-11-12 MX MX2014005874A patent/MX2014005874A/es unknown
- 2012-11-12 CN CN201280055937.8A patent/CN103930094A/zh active Pending
- 2012-11-12 SG SG11201401476TA patent/SG11201401476TA/en unknown
- 2012-11-12 BR BR112014011518A patent/BR112014011518A2/pt not_active IP Right Cessation
- 2012-11-12 PE PE2014000672A patent/PE20141337A1/es not_active Application Discontinuation
- 2012-11-12 EA EA201490960A patent/EA201490960A1/ru unknown
- 2012-11-12 IN IN3416DEN2014 patent/IN2014DN03416A/en unknown
- 2012-11-12 JP JP2014541363A patent/JP6275645B2/ja not_active Expired - Fee Related
- 2012-11-12 EP EP12798500.0A patent/EP2779995A1/en not_active Withdrawn
- 2012-11-12 SG SG10201707768RA patent/SG10201707768RA/en unknown
- 2012-11-13 TW TW101142278A patent/TWI574690B/zh not_active IP Right Cessation
-
2014
- 2014-04-15 ZA ZA2014/02756A patent/ZA201402756B/en unknown
- 2014-04-25 TN TNP2014000177A patent/TN2014000177A1/en unknown
- 2014-05-05 IL IL232480A patent/IL232480A0/en unknown
- 2014-05-07 MA MA36991A patent/MA35636B1/fr unknown
- 2014-05-13 CL CL2014001247A patent/CL2014001247A1/es unknown
- 2014-05-14 CO CO14103891A patent/CO6960546A2/es unknown
- 2014-05-14 GT GT201400094A patent/GT201400094A/es unknown
- 2014-10-21 HK HK14110470A patent/HK1197025A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EA201490960A1 (ru) | 2014-08-29 |
ZA201402756B (en) | 2015-04-29 |
AU2012339829A1 (en) | 2014-05-29 |
CA2855503A1 (en) | 2013-05-23 |
JP2014533283A (ja) | 2014-12-11 |
EP2779995A1 (en) | 2014-09-24 |
CN103930094A (zh) | 2014-07-16 |
AR088844A1 (es) | 2014-07-10 |
WO2013074432A1 (en) | 2013-05-23 |
IL232480A0 (en) | 2014-06-30 |
TW201325594A (zh) | 2013-07-01 |
SG10201707768RA (en) | 2017-10-30 |
IN2014DN03416A (zh) | 2015-06-26 |
PE20141337A1 (es) | 2014-10-16 |
SG11201401476TA (en) | 2014-10-30 |
NZ623844A (en) | 2016-09-30 |
GT201400094A (es) | 2017-09-28 |
CO6960546A2 (es) | 2014-05-30 |
KR20140093230A (ko) | 2014-07-25 |
MA35636B1 (fr) | 2014-11-01 |
TWI574690B (zh) | 2017-03-21 |
BR112014011518A2 (pt) | 2017-05-16 |
AU2012339829B2 (en) | 2016-05-12 |
JP6275645B2 (ja) | 2018-02-07 |
CL2014001247A1 (es) | 2014-10-17 |
MX2014005874A (es) | 2014-06-23 |
TN2014000177A1 (en) | 2015-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL229395A0 (en) | Adjusted release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-4)-5-n-methyl-h1 imidazol-1-yl)-3-(trifluoromethyl)phenyl] Benzamide is dissolved using organic acids | |
HK1226069A1 (zh) | 3,5 -二氨基-6-氯-n-(n-(4 -(4 -(2 -(己基(2,3,4,5,6 -五羥基己基)氨基)乙氧基)苯基)丁基)甲脒基)吡嗪-2-甲醯胺 | |
HK1217487A1 (zh) | 用於治療成癮的作為乙醛脫氫酶- 抑制劑的 -氧基- -二氫-吡啶- -基 -芐基 -苯甲酰胺衍生物 | |
ZA201101891B (en) | The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide | |
HRP20182059T1 (hr) | Polimorfi i soli 6-(1h-indol-4-il)-4-(5-{[4-(1-metiletil)-1-piperazinil]metil}-1,3-oksazol-2-il)-1h-indazola kao inhibitori pi3k, namijenjeni upotrebi u liječenju, primjerice, dišnih poremećaja | |
SG11201500499TA (en) | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors | |
DK2878598T3 (da) | Krystallinsk form af 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridin-2-carbonitril | |
IL268690A (en) | (4)- 1-(1-(S-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(1-methyl-H1-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridine-2 (H1)-Onat salts and their crystalline structures and pharmaceutical preparations containing them | |
IL237378B (en) | Derivatives of 1-(phenyl/pyrid-4-yl)-3-(phenyl-oxazolyl-5-(methyl-4,2,1,-triazole) and pharmaceutical compounds containing them | |
IL254132B (en) | A solid preparation of N-(4-(1(2,6-difluorobenzyl)-5-))dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxy-1,2,3 4-tetrahydrothiano[2,3-d]pyrimidine-6-yl)phenyl)-n-methoxyurea or its salt | |
HK1202237A1 (zh) | -二氯- -苯並 咪唑- -基 -吡唑- -羧酸的葡甲胺鹽製劑 | |
WO2013150545A3 (en) | Process for preparation of benzimidazole derivatives and salts thereof | |
IL234742A0 (en) | Salts of 5-[(2,21)]4]-2})-2-(r-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinoline-2(1h)- potency | |
IL220851A (en) | Process for the preparation of n - (2 - (2 - (4 - (2 - (7,6-dimethoxy-4,3-dihydro-iso-quinoline-2 - (1 h))) ethyl) phenyl) - h2 - tetrazole - 5-ram (5,4-dimethoxyphenyl) -4-oxo-h4-chromium-2-carboxamide methane-sulfonate, its intermediate and intermediate preparation process | |
HK1197025A1 (zh) | 即釋 -甲基- -吡啶基 -嘧啶基 氨基 -甲基- -咪唑- -基 三氟甲基 苯基 苯甲酰胺劑型 | |
SI2608789T1 (sl) | Terapevtske uporabe 1-(2-(2,4-dimetil-fenilsulfanil) fenil) piperazina | |
PL2943488T3 (pl) | Postacie soli megluminowej kwasu 2-((1r,4r)-4-(4-(5-(benzoksazol-2-iloamino)pirydyn-2-ylo)fenylo)cykloheksylo)octowego i ich zastosowania jako inhibitory dgat1 | |
PL394559A1 (pl) | Kapsulki zawierajace 4-[(4-metylopiperazyn-1ylo)metylo]-N-[4-metylo-3-[(4-pirydyn-3-ylopirymidyn-2-ylo)amino]fenylo]benzamid oraz sposób jej wytwarzania | |
PL392269A1 (pl) | Tabletka zawierająca 4-[(4-metylopiperazyn-1-ylo)metylo]-N-[4-metylo-3-[(4-pirydyn-3-ylopirymidyn-2-ylo)amino]fenylo]benzamid oraz sposób jej wytwarzania | |
PL387516A1 (pl) | Kompozycja farmaceutyczna zawierająca 4-[(4-metylopiperazyn-1-ylo)metylo]-N-[4-metylo-3-[(4-pirydyn-3-ylopirymidyn-2-ylo)amino]fenylo]benzamid, sposób jej wytwarzania oraz postacie leku zawierające tę kompozycję |